Our Pricing

Mounjaro vs Wegovy: Clinical Comparison for UK Patients

Wondering mounjaro vs wegovy which is better uk for your weight loss goals? Both injectable treatments are licensed by the MHRA for chronic weight management, but they work through different mechanisms and produce distinct clinical outcomes. At Cured Pharmacy, our UK prescribers help patients compare these options with transparent pricing from £135.00 and free online consultations.

How Mounjaro and Wegovy Work Differently

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK, whilst Wegovy contains semaglutide, a single GLP-1 receptor agonist [1]. This fundamental difference in mechanism explains why clinical trials show varying efficacy profiles between the two medications.

Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, creating a synergistic effect on appetite regulation and glucose metabolism [1]. Semaglutide works solely through GLP-1 pathways, which still produces significant weight loss but through a single mechanism [2].

Both medications slow gastric emptying, reduce appetite, and improve glycaemic control, but the dual-receptor activation in Mounjaro may explain the enhanced weight reduction observed in head-to-head comparisons [3]. Your UK prescriber will assess which mechanism suits your medical history and weight loss goals during your clinical consultation.

Clinical Trial Results: Mounjaro vs Wegovy Effectiveness

In the SURMOUNT-1 trial, patients taking Mounjaro 15mg achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. The STEP 1 trial showed Wegovy participants lost an average of 14.9% body weight over 68 weeks versus 2.4% with placebo [2].

Direct comparison data from the SURPASS-2 trial demonstrated that tirzepatide produced superior weight loss outcomes compared to semaglutide 1mg, with the highest tirzepatide dose achieving approximately 5-7kg greater weight reduction [3]. However, it's important to note that this trial used the diabetes-licensed dose of semaglutide rather than the higher Wegovy dose.

Both medications show sustained weight loss when combined with reduced-calorie diet and increased physical activity, as required by MHRA licensing conditions [1][2]. Individual responses vary significantly, and some patients may achieve better results or tolerate one medication better than the other, which is why personalised prescriber assessment is essential.

What the Numbers Mean for You

A 22.5% weight reduction for someone weighing 100kg means losing approximately 22.5kg, whilst 14.9% means approximately 14.9kg loss. These are average trial results — individual outcomes depend on adherence, lifestyle modifications, starting weight, and metabolic factors that your UK prescriber will discuss during consultation.

Side Effects: What to Expect with Each Treatment

Both Mounjaro and Wegovy share similar gastrointestinal side effects due to their GLP-1 activity, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][2]. These effects typically occur during dose escalation and diminish over time as your body adjusts to the medication.

In clinical trials, nausea occurred in approximately 29% of Mounjaro patients and 44% of Wegovy patients, though severity and duration varied [1][2]. Diarrhoea affected roughly 23% of Mounjaro users and 30% of Wegovy users. Most gastrointestinal symptoms were mild to moderate and resolved within weeks.

Rare but serious side effects include pancreatitis, gallbladder problems, and potential thyroid tumours (observed in animal studies) [1][2]. Both medications carry similar contraindications, including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your UK prescriber will screen for these conditions during your clinical assessment.

Managing Side Effects Effectively

Starting with lower doses and gradually titrating upwards, as prescribed by your UK clinician, significantly reduces the severity of gastrointestinal symptoms. Eating smaller meals, avoiding high-fat foods, and staying well-hydrated can further minimise discomfort during the initial treatment weeks.

Switching Between Wegovy and Mounjaro: Clinical Guidance

Patients may consider switching from Wegovy to Mounjaro if they've reached a weight loss plateau, experience intolerable side effects, or seek enhanced efficacy based on emerging clinical evidence [3]. Conversely, some may switch from Mounjaro to Wegovy due to cost considerations or better tolerance of the single-receptor mechanism.

When switching between these medications, your UK prescriber will typically recommend a washout period of 1-2 weeks to allow the previous medication to clear your system, though clinical protocols vary based on individual circumstances [4]. The new medication usually starts at the lowest therapeutic dose regardless of your previous dose level, then titrates upwards according to the licensed schedule.

It's essential to switch under medical supervision rather than self-directing changes, as both medications require careful dose escalation to minimise side effects and ensure safety [4]. At Cured Pharmacy, our clinical team provides switching guidance as part of your ongoing consultation, ensuring continuity of care throughout your weight management programme.

What Happens During the Switch

Your prescriber will review your weight loss progress, current side effects, and medical history before approving a switch. You'll receive detailed instructions on timing your final dose of the current medication, when to start the new treatment, and what side effects to monitor during the transition period.

Mounjaro vs Wegovy UK Pricing and Value Comparison

At Cured Pharmacy, Mounjaro starts from £135.00 per pen, whilst Wegovy is available from £135.00, with final pricing determined by your prescribed dose following clinical assessment. Both treatments include free UK prescriber consultation, discreet packaging, and dispensing by our GPhC-registered pharmacy team.

Cost-effectiveness depends on individual response rather than price alone. Some patients achieve their target weight loss more quickly with the higher-efficacy option, potentially requiring fewer months of treatment overall. Others may find the lower-priced option sufficient for their goals, making it more economical over time.

Unlike some online services, Cured Pharmacy displays transparent upfront pricing before you begin your consultation, with no hidden fees or subscription traps. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) ensures all prescriptions meet MHRA standards and represent genuine UK-licensed medication, never grey-market imports or unlicensed alternatives.

Which Treatment Is Right for Your Weight Loss Goals?

Choosing between Mounjaro and Wegovy depends on multiple factors including your BMI, previous weight loss attempts, medical history, budget, and tolerance for potential side effects. Patients seeking maximum weight reduction based on current clinical evidence may prefer Mounjaro, whilst those prioritising cost-effectiveness or proven long-term safety data may opt for Wegovy [1][2].

Your UK prescriber will assess your eligibility for either medication during your free online consultation, which takes under 3 minutes to complete. Both treatments require a BMI of 30 or above, or 27 or above with weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea, in line with NICE guidance [5].

At Cured Pharmacy, we offer both Mounjaro and Wegovy alongside alternative weight loss treatments including Saxenda and oral options like Orlistat, ensuring you have access to the full spectrum of MHRA-licensed weight management medications. Our clinical team provides ongoing support throughout your treatment journey, with prescription renewals and dose adjustments handled through simple follow-up consultations.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
4. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss medications work best when combined with a reduced-calorie diet and increased physical activity.